first broker upgrade: 5.10, page-11

Don Bradman,

"It also doesnt say much for Australian media's knowledge/interest in the bio-tech community. Maybe PXS have to waste taxpayer money on a synchotron to get noticed. Still Cochlear and CSL used to be well under $10 too! "


I spoke with PXS management a couple of years ago when they were doing the listing on the US. The reason for that listing was partly to do with the fact that US analysts understand these types of stocks better than the Aussies. This validates your post, they don't know how to cover these stocks.

PXS is to a certain extent a "bottom drawer" stock...the recent announcement has reduced the risks. I have no doubt that this will be fast tracked and given the FDA approval in due course.

Good luck to all that hold.